← Leaderboards
Holger Willenbring
University Of Pennsylvania
$13,377,791
Attributed
$25,857,069
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,279,569 · 14
By mechanism
UH3$6,887,844 · 1
R01$5,499,805 · 3
RC2$4,780,391 · 1
P30$4,460,001 · 6
DP1$3,896,814 · 1
UG3$2,346,696 · 1
Top collaborators
- Kenneth J Mclaughlin6 shared
- Kevin E Healy5 shared
- Matthias Hebrok5 shared
- Edward C Hsiao5 shared
- Stacey S Huppert5 shared
- Andreas Stahl5 shared
- Jacquelyn J. Maher3 shared
- Aras Nikodemas Mattis3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Kenneth J McLaughlin$1,801,345
- Douglas C Ewbank$8,828,587
- Amber Weiching Wang$93,994
- Julie Johnston$7,919,588
- Christopher Denman$773,798
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverHepatocyteCellsBaseIn VivoSourceLiver DiseasesCell TypeHepatologyPublishingTechnologyResearch PersonnelMouse ModelClinical TrialsFibrosisGene DeliveryProgramsReportingMemberLibrariesGrantGeneticCholangiocyteTissues
Grant awards (49)
Establishing patient-derived iPSCs as a platform for discovery research in NAFLD$1,614,997
RC2 · FY2025 · DK
UCSF Liver Center$1,211,250
P30 · FY2025 · DK · contact PI
Next-generation human liver gene therapy$785,743
DP1 · FY2025 · DK · contact PI
Administrative Core$372,631
P30 · FY2025 · DK · contact PI
Establishing patient-derived iPSCs as a platform for discovery research in NAFLD$1,550,397
RC2 · FY2024 · DK
UCSF Liver Center$1,211,250
P30 · FY2024 · DK · contact PI
Next-generation human liver gene therapy$754,269
DP1 · FY2024 · DK · contact PI
Pilot & Feasibility Grant Program$166,086
P30 · FY2024 · DK · contact PI
Enrichment Program$65,956
P30 · FY2024 · DK · contact PI
Establishing patient-derived iPSCs as a platform for discovery research in NAFLD$1,614,997
RC2 · FY2023 · DK
Next-generation human liver gene therapy$785,647
DP1 · FY2023 · DK · contact PI
Pilot & Feasibility Grant Program$166,085
P30 · FY2023 · DK · contact PI
Enrichment Program$65,955
P30 · FY2023 · DK · contact PI
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus$2,287,847
UH3 · FY2022 · DK
Next-generation human liver gene therapy$785,601
DP1 · FY2022 · DK · contact PI
Targeting AAV vectors to cell types involved in alcohol-induced liver injury$316,666
R01 · FY2022 · AA · contact PI
Pilot & Feasibility Program$160,158
P30 · FY2022 · DK · contact PI
Enrichment Program$84,188
P30 · FY2022 · DK · contact PI
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus$2,294,476
UH3 · FY2021 · DK
Next-generation human liver gene therapy$785,554
DP1 · FY2021 · DK · contact PI
Targeting AAV vectors to cell types involved in alcohol-induced liver injury$316,666
R01 · FY2021 · AA · contact PI
Pilot & Feasibility Program$160,158
P30 · FY2021 · DK · contact PI
Targeting AAV vectors to cell types involved in alcohol-induced liver injury$93,282
R01 · FY2021 · AA · contact PI
Enrichment Program$84,188
P30 · FY2021 · DK · contact PI
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus$2,305,521
UH3 · FY2020 · DK
Building a functional biliary system from hepatocytes$434,900
R01 · FY2020 · DK
Targeting AAV vectors to cell types involved in alcohol-induced liver injury$316,666
R01 · FY2020 · AA · contact PI
Pilot & Feasibility Program$154,991
P30 · FY2020 · DK · contact PI
Enrichment Program$79,060
P30 · FY2020 · DK · contact PI
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus$1,170,825
UG3 · FY2019 · DK
Building a functional biliary system from hepatocytes$434,900
R01 · FY2019 · DK
Targeting AAV vectors to cell types involved in alcohol-induced liver injury$316,785
R01 · FY2019 · AA · contact PI
Pilot & Feasibility Program$155,755
P30 · FY2019 · DK · contact PI
Enrichment Program$80,276
P30 · FY2019 · DK · contact PI
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus$1,175,871
UG3 · FY2018 · DK
Building a functional biliary system from hepatocytes$477,173
R01 · FY2018 · DK
Targeting AAV vectors to cell types involved in alcohol-induced liver injury$330,302
R01 · FY2018 · AA · contact PI
Pilot & Feasibility Program$158,629
P30 · FY2018 · DK · contact PI
Enrichment Program$83,385
P30 · FY2018 · DK · contact PI
Building a functional biliary system from hepatocytes$550,831
R01 · FY2017 · DK
Building a functional biliary system from hepatocytes$549,895
R01 · FY2016 · DK
Myofibroblast-to-hepatocyte conversion as a therapy for alcoholic liver disease$182,091
R21 · FY2014 · AA · contact PI
Myofibroblast-to-hepatocyte conversion as a therapy for alcoholic liver disease$225,927
R21 · FY2013 · AA · contact PI
Liver regeneration with stems cells of uniparental origin$304,284
R01 · FY2011 · DK
Liver regeneration with stems cells of uniparental origin$307,358
R01 · FY2010 · DK
Liver regeneration with stems cells of uniparental origin$214,277
R01 · FY2009 · DK
Liver regeneration with stems cells of uniparental origin$103,616
R01 · FY2009 · DK
Liver regeneration with stems cells of uniparental origin$345,579
R01 · FY2008 · DK
Liver regeneration with stems cells of uniparental origin$86,625
R01 · FY2008 · DK